Infection year 2025; rounded bottoming formation.- Infection year 2025; rounded bottoming formation.
- business is improving starting 2025
Key facts today
−0.330 USD
−3.16 B USD
2.87 B USD
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
ISIN
AR0666228538
FIGI
BBG01MDJMR28
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Related stocks
MRNA: Bullish Setup Ahead of Earnings & FOMCMRNA: Bullish Setup Ahead of Earnings & FOMC
Moderna (MRNA) appears to have found a bottom near $23.50, based on recent price behavior. Following that level, the stock began accumulating, suggesting renewed buying interest. This was confirmed when MRNA decisively broke above $28.50, signaling a sh
Bullish Analysis for Moderna (MRNA)Recent Price Action Shows Strength MRNA has shown significant bullish momentum since mid-May 2025, rising from around $24 to current levels above $34, representing a 40%+ gain. The stock has formed a series of higher lows and higher highs, establishing a clear uptrend.
Key Bullish Factors:
Positiv
MRNA Approaching Trend Shift After Multi-Month DeclinePotential trend flip on the Moderna Chart for the first time since May 2024. I use a default doubled cloud on the daily timeframe 18/52/104/26. I find this to be superior to the default cloud on both backtesting and forward testing over the past decade on any chart.
Ideal bullish entry conditions
Retest comingBullish flag forming to test the ~$35 resistance again. Earnings coming up on 08/01. I expect the flag breakout before earnings. I have calls exp 08/01 strike 31.5. SL triggers if a daily candle breaks down the support area and closes below 30.30.
Generational bottom is in. Breakout has begunAfter forming a bullish wedge for a few months, the price went sideways for another 3 months which is a very good sign that the bottom is in.
MRNA looking strong at cmpModerna remains in a precarious transition phase—from COVID-revenue dependency toward a diversified vaccine portfolio. Technically, momentum favors upside in the short-term, but fundamentals and macro-regulatory factors suggest caution. If its RSV and flu/COVID combo rollouts succeed and regulatory
$MRNAIn the daily chart I can see the falling wedge is ready to brake out. 1 hour chart I like the accumulation in the last 2 months. brake out is expected. the target is 49 if you see momentum.
as long as the price stay above 24.70.
MRNA: The Wager No One Wants to Talk AboutModerna (MRNA) has become a pariah in many portfolios. Between reputational overhangs, political weaponization of its COVID success, and fresh regulatory pressures like the labeling requirement just triggered by Florida, the company has seemingly absorbed wave after wave of bad press.
But that’s th
$MRNA – Long-Term Setup Brewing | Major Move Incoming?Moderna ( NASDAQ:MRNA ) may be gearing up for a multi-month reversal after a prolonged downtrend. Price action is compressing in a tight base, suggesting a potential 6+ month breakout could be in the cards.
📊 Key Technical Notes:
Trading near long-term support with signs of accumulation
Bullish d
See all ideas
Curated watchlists where MRNAC is featured.
